Capricor Therapeutics (CAPR) Misses Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Idea Q3 2026: Ryanair (RYAAY) PT Raised to $79 at Bernstein SocGen
- Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
- Trump praises Dell family for contributions to Trump Accounts, urges to buy Dell computers
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
